ArticleWorld journal of gastrointestinal oncology2012
Follow-up of intestinal metaplasia in the stomach: When, how and why.
Article in World journal of gastrointestinal oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Global prevalence of gastric intestinal metaplasia: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Guideline
- Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Diagnostic yield of the light blue crest sign in gastric intestinal metaplasia: a meta-analysis.PloS one · 2014Pooled it
- Association of high organochlorine pesticide serum levels with oxidative stress in intestinal metaplasia and gastric cancer.Heliyon · 2025Article
- Gastric intestinal metaplasia regression in United States population: A retrospective longitudinal study.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- The role of cuproptosis in gastric cancer.Frontiers in immunology · 2024Review
- Intestinal Metaplasia Associated with Symptoms of Dyspepsia.Research square · 2023Article
- Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression.Cancer cell · 2023Article
- The utility of endoscopy prior to bariatric surgery: an 11-year retrospective analysis of 885 patients.Surgical endoscopy · 2023Article
- Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis.Virchows Archiv : an international journal of pathology · 2022Article
- Identifying the pre-malignant stomach: from guidelines to practice.Translational gastroenterology and hepatology · 2022Review
- Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer.Cancers · 2021Review
- Chronic Autoimmune Gastritis: Modern Diagnostic Principles.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment.BMC cancer · 2021Article
- Gastric cancer: lessons learned from high-incidence geographic regions.Journal of gastrointestinal oncology · 2021Review
- A meta-analysis and systematic review on subtypes of gastric intestinal metaplasia and neoplasia risk.Cancer cell international · 2021Review
- Recent advances in the detection and management of early gastric cancer and its precursors.Frontline gastroenterology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains the second most frequent cause of cancer-related mortality in the world. Screening programs in some Asian countries are impractical in the majority of other countries worldwide. Therefore, follow-up of precancerous lesions is advisable for secondary gastric cancer prevention. Intestinal metaplasia (IM) is recognized as a precancerous lesion for gastric cancer, increasing the risk by 6-fold. IM is highly prevalent in the general population, being detected in nearly 1 of every 4 patients undergoing upper endoscopy. The IM prevalence rate is significantly higher in patients with Helicobacter pylori (H. pylori) infection, in first-degree relatives of gastric cancer patients, in smokers and it increases with patient age. IM is the "breaking point" in the gastric carcinogenesis cascade and does not appear to regress following H. pylori eradication, although the cure of infection may slow its progression. Gastric cancer risk is higher in patients with incomplete-type IM, in those with both antral and gastric body involvement, and the risk significantly increases with IM extension over 20% of the gastric mucosa. Scheduled endoscopic control could be cost-effective in IM patients, depending on the yearly incidence of gastric cancer in IM patients, the stage of gastric cancer at diagnosis discovered at surveillance, and the cost of endoscopy. As a pragmatic behavior, yearly endoscopic control would appear justified in all IM patients with at least one of these conditions: (1) IM extension > 20%; (2) the presence of incomplete type IM; (3) first-degree relative of gastric cancer patients; and (4) smokers. In the remaining IM patients, a less intensive (2-3 years) could be proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.